Enhancing Antibody Validation: Insights from Kevin Harvey's Presentation at the University of Bath
Organized by the University of Bath and supported by CiteAb, the Antibody Validation Meeting serves as a premier platform for advocates, experts, and enthusiasts in antibody validation to convene and share insights. This year, our President, Kevin Harvey delivered a talk focusing on Aviva’s innovative “Use of High Throughput SPR to Characterize Antibodies to Common Cancer Biomarkers.”
In his talk, Kevin Harvey delved into the critical role that high throughput surface plasmon resonance (SPR) plays in the characterization and validation of antibodies, especially those targeting prevalent cancer biomarkers. He emphasized how this advanced technique enables precise measurement of antibody interactions, ensuring high reproducibility and reliability—key factors in successful cancer research and diagnostics. You can watch his full presentation here.
The importance of reproducibility and reliability of antibodies cannot be overstated. Inconsistent antibody performance has led to flawed experimental outcomes and hinder scientific progress, which is well documented. At Aviva Systems Biology, we are dedicated to addressing these challenges by developing robust validation methods that set new benchmarks for antibody quality.
Through active participation in collaborative efforts and ongoing discussions at events like the Antibody Validation Meeting, we aim to enhance the quality of our antibody technologies. Our commitment to excellence drives us to continually improve our products and support the scientific community in achieving breakthrough discoveries.
If you’d like to learn more about our antibody validation efforts or have questions or comments, we invite you to reach out to us at Info@avivasysbio.com or TechSupport@avivasysbio.com. Join us in our mission to advance antibody validation and ensure the reliability of research outcomes worldwide.
About Aviva Systems Biology
Founded in 2002, Aviva Systems Biology supports scientists in their basic research, preclinical, drug development, and diagnostics workflows. With an extensive portfolio of nearly 500,000 products for antibodies, proteins, and immunoassays and over 20 years of expertise in antibody and protein production, scientists can find the unique reagents and support they need for success in their work.